Short answer
Exelixis Inc (EXEL) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended July 3, 2026.
Exelixis Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended July 3, 2026
- Corporate update accompanying Exelixis’ quarterly results
- Full financial figures and guidance in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $628.7M, up from $568.3M, driven by cabozantinib product revenue of $573.0M
- GAAP diluted EPS $0.82, up from $0.65, with buybacks reducing diluted shares to 259.7M from 284.4M
- FY2026 revenue guidance reduced to $2.500B-$2.550B from $2.525B-$2.625B
- FDA decision on zanzalintinib CRC application targeted for December 3, 2026, excluding potential launch revenue from guidance
- $750M additional repurchase authorization, following $2.9B of cumulative buybacks and 93.3M shares retired
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Exelixis Inc 8-K filings
Get the next EXEL 8-K as it lands
Follow EXEL for push alerts, or ask the research agent what this filing means.